Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$2.03B
EBITDA Margin
40.34%
TTM Avg
23.31%
3Y Avg
-20.04%
5Y Avg
-112.62%
Market Cap
$2.00B
EBITDA Margin
7.12%
TTM Avg
6.21%
3Y Avg
-1.19%
5Y Avg
-11.55%
Market Cap
$2.06B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
Market Cap
$2.06B
EBITDA Margin
39.14%
TTM Avg
19.43%
3Y Avg
-11.55%
5Y Avg
-189.29%
Market Cap
$1.97B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $2.03B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.03B | 7.00% | 6.53% | 5.54% | 5.31% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.03B | 40.34% | 23.31% | -20.04% | -112.62% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 7.12% | 6.21% | -1.19% | -11.55% |
| Alvotech (ALVO)vs › | $2.06B | 19.79% | 20.20% | -178.47% | -247.76% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.06B | 1.74% | -0.52% | 3.36% | 2.51% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | 39.14% | 19.43% | -11.55% | -189.29% |
| Immunome, Inc. (IMNM)vs › | $1.97B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 0.15% | 1.29% | -6.34% | -9.86% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.95B | -13.52% | -19.53% | -24.36% | -23.78% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
